Full Press Release Details
• News Releases
• Gilead-Sciences-to-Release-Third-Quarter-2026-Financial-Results-on-Thursday-October-29-2026
Share Article
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.
A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Jacquie Ross, CFA – Investors investor_relations@gilead.com
Share Article
Other News
Some of the content on this page is not intended for users outside the U.S.
• Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026October 15, 2026
• Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV PreventionSeptember 16, 2026
• Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the CaribbeanSeptember 15, 2026
• Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of MedicinesSeptember 8, 2026
• U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex RegimensAugust 27, 2026
• Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor ConferencesAugust 26, 2026
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences